SES/IMS
15.12.2021 08:52:11 CET | Business Wire | Press release
SES’s satellite-based trunking services will enable leading Colombian fibre optic networks service provider Integra Multisolutions (IMS) to extend and enhance fibre-like connectivity for Colombian municipalities with fewer than 100,000 inhabitants located out of the reach of terrestrial infrastructure, SES announced today. The new service will begin on SES’s O3b medium earth orbit (MEO) constellation and later migrate onto O3b mPOWER, SES’s next-generation MEO system, in 2022 when service will expand to additional cities.
The first site to be connected will be Puerto Leguizamo, a municipality located in the Putumayo Department in the southern border region of the country. SES and IMS will go on to deliver service to other sparsely populated cities across Colombia that experience poor or inconsistent connectivity services.
SES’s Trunk mPOWERED service will equip IMS to enable local Internet service providers to serve a combination of enterprise, residential, MNO and civilian government projects. IMS is among the first companies in Latin America to sign up for the O3b mPOWER system, which can deliver low-latency, high-speed, uncontended services from tens of megabits to multiple gigabits per second to a single site.
According to the Colombian Ministry of Telecommunications, fixed broadband subscriptions in the country reached 8.22 million in 2021, which translates to 16.10 subscriptions per 100 people. However, the National Administrative and Statistics Department (Dane) revealed earlier this year the results of the Survey of Information and Communication Technologies in Households (ENTIC Hogares) showing only 56.5% of the households surveyed have an internet connection. The survey identified an important difference between households in the main cities, where 66.6% have internet access, and those in rural and dispersed areas, where only 23.9% of the households do. The Putumayo Department is among the regions with challenges to access reliable connectivity services.
“By working together with SES, we are able to quickly and cost-effectively expand our network in underserved and tough-to-reach areas helping to address the digital divide for these communities,” said Juan Carlos Hernandez Mendoza, CEO of IMS Group. “Our goal is to provide our end users the best quality of service across Colombia, which means access to high-performing services at all times, no matter where they are. The capabilities of the proven O3b MEO fleet, and the scalability and flexibility of the upcoming O3b mPOWER services combined with SES satellite network and IMS fibre optics networks expertise, allow us to achieve exactly that.”
“Our multi-orbit satellite solutions have been bringing reliable connectivity services across Colombia for almost 10 years,” said Omar Trujillo, Americas Vice President of Fixed Data Sales at SES. “We are delighted to partner with IMS to extend terrestrial networks with the revolutionary capabilities of the O3b mPOWER constellation and deliver fibre-like Internet access to Colombians wherever they live.”
Follow us on:
Twitter
| Facebook
| YouTube
| LinkedIn
| Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,500 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About IMS
IMS was created in 2016, since then IMS is becoming the main PARTNER for all the small and medium Internet Service Providers in Colombia through terrestrial telecom technologies specialized in fiber optic networks, Networking Engineering, ISP Tech Solutions, supply chain, and many more. Currently IMS has more than 100,000 kilometres of available fiber throughout Colombia and sells more than 300 Gbps of fiber optic capacity to more than 250 corporate customers, becoming a very important provider for internet carriers in the region. For more information about IMS go to www.ims.net.co .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214006318/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom